The Association of G9a Protein and the Outcome of Patients With Cervical Cancer

Completed

• Conditions: Cervical Cancer

• Registration Number: NCT01505751
• Lead Sponsor: Far Eastern Memorial Hospital

Brief Summary

G9a protein was approved to be highly associated with recurrence of breast cancer, gastric cancer, hepatocellular cancer, prostate cancer and lung cancer. Therefore, the aim of this study was to clarify the association and G9a protein and cervical cancer by analyzing the immunohistochemical staining of G9a protein to the histopathologic specimen of cervical cancer and clinical data.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-12-27
• Study First Submitted QC: 2012-01-06
• Study First Posted: 2012-01-09
• Study Start: 2012-02
• Primary Completion: 2015-02
• Study Completion: 2015-02
• Status Verified: 2015-07
• Last Update Submitted: 2016-09-04
• Last Update Posted: 2016-09-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 69

Inclusion Criteria

• cases with cervical cancer

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
determine whether G9a protein is a risk factor of overall survival of patients with cervical cancer	From the date of primary treatment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months

Secondary Outcome Measures

Name	Time	Method
determine whether G9a protein is a risk factor of progression-free survival of patients with cervical cancer	From the date of primary treatment until the date of first documented progression or last follow-up, whichever came first, assessed up to 100 months

Trial Locations

Locations (1)

Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital; 🇨🇳 Banqiao, New Taipei, Taiwan